Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000821:virology*; D019943:Amino Acid Substitution; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D000077560:Enfuvirtide; D019143:Evolution, Molecular; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects* / Q000235:genetics* / Q000627:therapeutic use; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D019713:Receptors, CCR5; D017422:Sequence Analysis, DNA; D014766:Viremia / Q000188:drug therapy / Q000821:virology
D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D019713:Receptors, CCR5; D000077560:Enfuvirtide